Research Topics
| Siqing FuSummaryAffiliation: The University of Texas Country: USA Publications
| Collaborators
|
Detail Information
Publications
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancerSiqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Gynecol Oncol 126:47-53. 2012..On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer...- Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experienceSiqing Fu
Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 30:2891-6. 2012..Patients with advanced malignancies referred for early clinical trials have a short life expectancy. We designed this survey to ascertain the status of advance care planning in this population... - Overcoming platinum resistance through the use of a copper-lowering agentSiqing Fu
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Mol Cancer Ther 11:1221-5. 2012..Evaluation of this novel strategy is warranted in larger studies to assess the efficacy of this approach for treating platinum-resistant advanced epithelial ovarian cancer in patients with high copper levels... 
Targeting Aurora kinases in ovarian cancerSiqing Fu
Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
Expert Opin Ther Targets 10:77-85. 2006..The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment...- Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activitySiqing Fu
Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Mol Cancer Ther 10:1300-7. 2011..HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases... - Development of curcumin as an epigenetic agentSiqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:4670-6. 2010..The development of curcumin as an epigenetic agent warrants further preclinical and clinical studies to explore its diversity and efficacy in cancer treatment and in combination with other anticancer agents... - Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials programSiqing Fu
Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 29:3547-52. 2011..This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy... 
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerSiqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 117:1661-9. 2011..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer...- Clinical application of oxaliplatin in epithelial ovarian cancerS Fu
Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77230 1439, USA
Int J Gynecol Cancer 16:1717-32. 2006..This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment... - KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitorsIgnacio Garrido-Laguna
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 7:e38033. 2012..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents... - Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experienceDavid S Hong
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Clin Colorectal Cancer 11:297-303. 2012..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials... - Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia Maria Tsimberidou
Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 18:6373-83. 2012..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations... - PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsFilip Janku
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 73:276-84. 2013..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration... - Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liverApostolia M Tsimberidou
Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Chemother Pharmacol 71:389-97. 2013..Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients... - Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experienceJennifer Wheler
Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Biostatistics, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 18:2922-9. 2012.... - A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liverApostolia M Tsimberidou
Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer 116:4086-94. 2010..The authors of this report conducted a phase 1 study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases... - Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvementApostolia M Tsimberidou
Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Chemother Pharmacol 68:247-53. 2011..The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement... - PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsFilip Janku
The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 30:777-82. 2012..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance... - Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapyHenrique A Parsons
Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Nutr Cancer 64:206-17. 2012..171). In conclusion, body composition was not significantly associated with toxicities or survival in our small sample... - Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastasesLuis H Camacho
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Clin Colorectal Cancer 9:311-4. 2010.... - PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancersFilip Janku
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 6:e22769. 2011..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis... - Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 118:1422-8. 2012.... - Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3Siqing Fu
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Cancer Biol Ther 13:1034-41. 2012..The growth-inhibitory effect was accompanied by reduction in expression of histone 3 and an increase in apoptosis. We conclude that VE 465 enhances the efficacy of carboplatin agents in ovarian carcinoma... - PIK3CA mutations in advanced cancers: characteristics and outcomesFilip Janku
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Oncotarget 3:1566-75. 2012..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors... - Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosisApostolia M Tsimberidou
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Hepatogastroenterology 59:960-4. 2012..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis... - Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosisYanfang Li
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Am J Obstet Gynecol 200:177.e1-9. 2009..The objective of the study was to investigate whether azacitidine sensitizes platinum-resistant ovarian cancer cells to carboplatin and the possible mechanisms involved... - Mechanistic basis for overcoming platinum resistance using copper chelating agentsZheng D Liang
Department of Molecular Pathology, Unit 951, Room 2SCR4 3025, The University of Texas MD Anderson Cancer Center, 7435 Fannin Blvd, Houston, TX 77054, USA
Mol Cancer Ther 11:2483-94. 2012..This study reveals the mechanistic basis for using copper chelation to overcome cDDP resistance in clinical investigations... - Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experienceHazem El-Osta
Department of Investigational Therapeutics, Phase 1 Program Unit 455, Division of Cancer Medicine, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
Oncologist 16:1292-8. 2011..Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies... - Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignanciesRazelle Kurzrock
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 118:6144-51. 2012..In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients with advanced solid tumors... - Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center ExperienceAung Naing
Department of Investigational Cancer Therapeutics Phase 1 Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer 117:5142-50. 2011..Therefore, the concurrent use of complementary and alternative medicine (CAM) in patients with advanced malignancies seen in a dedicated phase 1 clinic was evaluated... - PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitorsFilip Janku
Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
Mol Cancer Ther 10:558-65. 2011..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations... - Update on aurora kinase inhibitors in gynecologic malignanciesXia Tao
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Recent Pat Anticancer Drug Discov 3:162-77. 2008..In this review, we summarize the most recent advances in preclinical studies and clinical trials of patented Aurora kinase inhibitors for gynecologic tumors... - Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvementApostolia M Tsimberidou
Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Chemother Pharmacol 66:1087-93. 2010..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement... - Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancerGerald S Falchook
Department of Investigational Cancer Therapeutics Phase I Program, U T MD Anderson Cancer Center, Houston, TX, USA
Oncotarget 4:118-27. 2013..Preclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models... - Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological ActivityJohn Moroney
Authors Affiliations Departments of Investigational Cancer Therapeutics Phase I Clinical Trials Program and Gynecologic Oncology, MD Anderson Cancer Center, Houston, Texas and Wright Patterson Medical Center, WPAFB, Dayton, Ohio
Clin Cancer Res 18:5796-805. 2012..Preclinical data suggest that combining the mTOR/hypoxia-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to anthracyclines... - Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatmentIgnacio Garrido-Laguna
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 16:4031-7. 2010.... - Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancerHong Zheng
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Am J Obstet Gynecol 201:367.e1-6. 2009..To investigate the role of cyclin G1 and cyclin B1 in ovarian tumorigenesis... - Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrestHong Zheng
Department of Gynecologic Oncology, Unit 1362, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street, Houston, Texas 77030, USA
Pharm Res 25:2272-82. 2008..DDAP improves platinum solubility which may reduce systemic toxicity and be more efficacious than cisplatin in killing tumor cells... - Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapyMacus Tien Kuo
Department of Molecular Pathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77054, USA
Cancer Res 72:4616-21. 2012.... - Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumorsAung Naing
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 18:2625-31. 2012..Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R)... - The changing face of phase 1 cancer clinical trials: new challenges in study requirementsBarbara S Craft
Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 115:1592-7. 2009..Although both phase 1 and phase 2 trials had substantial study requirements, those for the phase 1 studies were significantly higher. The successful conduct of early-phase clinical trials requires significant research infrastructure... - What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?X Cheng
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Chemother 21:566-72. 2009..Seventeen (26.6%) patients had improved performance status scores. Bevacizumab combined with chemotherapy showed promising clinical benefits, with significant response of serum CA125 concentration and moderate adverse effects... - Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunctionYanfang Li
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 1155 Pressler Street, Houston, TX 77030, USA
Gynecol Oncol 106:375-80. 2007..We sought to investigate the toxicity and efficacy of PLD in gynecologic cancer patients with CKD... - Hormonal therapy in ovarian cancerH Zheng
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
Int J Gynecol Cancer 17:325-38. 2007..Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials... - Systemic anticancer therapy in gynecological cancer patients with renal dysfunctionY F Li
Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
Int J Gynecol Cancer 17:739-63. 2007..We also review the formulae commonly used to estimate creatinine clearance, including Cockcroft-Gault, Chatelut, Jelliffe, Wright, and the Modification of Diet in Renal Disease study formulae...